FDA Approval For Rafa’s Life-saving Midazolam Autoinjector for US DoD’s Advanced Anticonvulsant System Program
Jerusalem-based Rafa Laboratories LTD. (“Rafa“) is pleased to announce the U.S. Food and Drug Administration has approved its “first in market” 10 mg midazolam autoinjector
eggXYt Brings Ultimate Solution to Prevent Annual Killing of Billions of Male Chicks!
eggXYt, a Jerusalem-based genetic tech startup, has solved the problem of the killing of male chicks and is planning to introduce its technology into the
With Added $25M+ Financing, Nectin Therapeutics Initiates Patient Dosing in Advanced Solid Tumors NTX1088 Phase 1 Trial
Nectin Therapeutics Ltd., (Nectin) a Jerusalem-based biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, started the dosing of the
Myeloma Investment Fund Invests in KAHR’s Lead Immunotherapy Drug for Multiple Myeloma Treatment
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation‘s (MMRF) venture philanthropy subsidiary, has invested in KAHR, a clinical-stage biotech company, to explore the
Alpha Tau and MIM Software Are Collaborating On Alpha DaRT Treatment Planning
Jerusalem-based Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau“), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”),
Visit Image Navigation’s Latest Dental Surgical Navigational Systems at MIXiii BioConference in Jerusalem, Nov 9-10, 2022
Image Navigation Ltd., a pioneer in surgical navigation systems, will present their second generation Image Guided Implantology (IGI) system at the Jerusalem Ecosystem Booth at
Immunyx Pharma Part of Global Consortium CanceRNA Developing RNA-based Cancer Vaccine
Immunyx Pharma is member of CanceRNA , a global consortium applying RNA-based therapeutics to successfully unlock anti-cancer immune responses. The consortium is led by Professor
Positive Preliminary Phase 1 Data for Oramed Subsidiary Oravax’s Oral Covid-19 Vaccine
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its
Mirror Biologics, Inc. Closes Out $30M Series A Investment Round with Additional $20M
Mirror Biologics, Inc., a clinical-stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round
